- Home
- CYCN vs EDSA Comparison
CYCN vs EDSA Comparison
Compare CYCN & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- EDSA
- Stock Information
- Founded
- CYCN 2018
- EDSA 2015
- Country
- CYCN United States
- EDSA Canada
- Employees
- CYCN N/A
- EDSA N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- CYCN Health Care
- EDSA Health Care
- Exchange
- CYCN Nasdaq
- EDSA Nasdaq
- Market Cap
- CYCN 7.5M
- EDSA 6.2M
- IPO Year
- CYCN N/A
- EDSA N/A
- Fundamental
- Price
- CYCN $2.62
- EDSA $2.35
- Analyst Decision
- CYCN
- EDSA Strong Buy
- Analyst Count
- CYCN 0
- EDSA 1
- Target Price
- CYCN N/A
- EDSA $21.00
- AVG Volume (30 Days)
- CYCN 31.8K
- EDSA 31.4K
- Earning Date
- CYCN 03-04-2025
- EDSA 05-09-2025
- Dividend Yield
- CYCN N/A
- EDSA N/A
- EPS Growth
- CYCN N/A
- EDSA N/A
- EPS
- CYCN N/A
- EDSA N/A
- Revenue
- CYCN $2,000,000.00
- EDSA N/A
- Revenue This Year
- CYCN N/A
- EDSA N/A
- Revenue Next Year
- CYCN N/A
- EDSA N/A
- P/E Ratio
- CYCN N/A
- EDSA N/A
- Revenue Growth
- CYCN N/A
- EDSA N/A
- 52 Week Low
- CYCN $1.27
- EDSA $1.55
- 52 Week High
- CYCN $9.47
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- CYCN 45.98
- EDSA 50.89
- Support Level
- CYCN $2.44
- EDSA $2.37
- Resistance Level
- CYCN $2.85
- EDSA $2.55
- Average True Range (ATR)
- CYCN 0.19
- EDSA 0.11
- MACD
- CYCN 0.02
- EDSA -0.01
- Stochastic Oscillator
- CYCN 29.46
- EDSA 25.93
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.